PEAK6 Investments’s Fulgent Genetics FLGT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-40,000
Closed -$1.07M 4410
2023
Q3
$1.07M Buy
+40,000
New +$1.37M ﹤0.01% 1795
2023
Q2
Sell
-22,200
Closed -$693K 4141
2023
Q1
$693K Sell
22,200
-30,900
-58% -$994K ﹤0.01% 2126
2022
Q4
$1.58M Sell
53,100
-12,200
-19% -$437K 0.01% 1533
2022
Q3
$2.49M Sell
65,300
-42,800
-40% -$2.15M 0.01% 1367
2022
Q2
$5.89M Buy
108,100
+64,700
+149% +$3.56M 0.01% 1248
2022
Q1
$2.71M Sell
43,400
-82,800
-66% -$5.45M 0.01% 1597
2021
Q4
$12.7M Buy
126,200
+73,500
+139% +$6.46M 0.03% 609
2021
Q3
$4.74M Buy
52,700
+51,600
+4,691% +$4.69M 0.01% 1194
2021
Q2
$101K Buy
+1,100
New +$87.8K ﹤0.01% 4391

Other funds holding FLGT

PEAK6 Investments's FLGT Position: Q2 2024 in Review

PEAK6 Investments sold out of Fulgent Genetics (FLGT) in Q2 2024, closing a stake of 103 shares — an estimated $2.23K sold.

PEAK6 Investments first reported a position in FLGT in Q3 2021 and held it in 10 quarters. The position peaked at $1.25M in Q4 2022. 173 funds tracked by Wall St. Rank hold FLGT as of Q2 2024.

  • PEAK6 Investments reported no remaining Fulgent Genetics position as of Q2 2024 after selling out during the quarter.
  • PEAK6 Investments sold 103 Fulgent Genetics shares in Q2 2024, an estimated $2.23K.
  • PEAK6 Investments first reported a position in Fulgent Genetics in Q3 2021 and held it in 10 quarters.
  • PEAK6 Investments's Fulgent Genetics position peaked at $1.25M in Q4 2022.
  • 173 funds tracked by Wall St. Rank held Fulgent Genetics as of Q2 2024.

Based on PEAK6 Investments's 13F filing for Q2 2024, filed 14 Aug 2024.